Universe Pharmaceuticals Stock Analysis
| UPC Stock | USD 3.50 0.23 7.03% |
Universe Pharmaceuticals is overvalued with Real Value of 3.14 and Hype Value of 2.81. The main objective of Universe Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Universe Pharmaceuticals is worth, separate from its market price. There are two main types of Universe Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Universe Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Universe Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. Universe Stock Analysis Notes
The company has Price to Book (P/B) ratio of 0.03. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Universe Pharmaceuticals recorded a loss per share of 255.68. The entity had not issued any dividends in recent years. The firm had 1:40 split on the 24th of March 2025. Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited. Universe Pharmaceuticals is traded on NASDAQ Exchange in the United States. For more information please call Gang Lai at 86 79 6840 3309 or visit https://www.universe-pharmacy.com.Universe Pharmaceuticals Quarterly Total Revenue |
|
Universe Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Universe Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Universe Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Universe Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 23.02 M. Reported Net Loss for the year was (8.73 M) with profit before taxes, overhead, and interest of 6.07 M. | |
| Universe Pharmaceuticals has about 28.58 M in cash with (9.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31. | |
| Latest headline from finance.yahoo.com: Universe Pharmaceuticals Reports First Half 2025 Earnings |
Universe Pharmaceuticals Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Universe Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View |
Universe Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Universe Pharmaceuticals' ESG score is a quantitative measure that evaluates Universe Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Universe Pharmaceuticals' operations that may have significant financial implications and affect Universe Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Universe Stock Institutional Investors
| Shares | Ubs Group Ag | 2025-03-31 | 266 | Millennium Management Llc | 2024-12-31 | 0.0 | Renaissance Technologies Corp | 2024-12-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 0.0 | Sabby Management Llc | 2025-03-31 | 0.0 | Anson Funds Management Lp | 2025-03-31 | 0.0 | Mml Investors Services Inc | 2024-12-31 | 0.0 | Xtx Topco Ltd | 2024-12-31 | 0.0 | Quadrature Capital Llp | 2024-12-31 | 0.0 | Two Sigma Securities, Llc | 2024-12-31 | 0.0 |
Universe Market Capitalization
The company currently falls under 'Nano-Cap' category with a total capitalization of 1.84 M.Universe Profitablity
The company has Net Profit Margin of (0.38) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.62) %, which entails that for every $100 of revenue, it lost $0.62.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.14) | |
| Return On Capital Employed | (0.19) | (0.18) | |
| Return On Assets | (0.15) | (0.14) | |
| Return On Equity | (0.22) | (0.21) |
Management Efficiency
Universe Pharmaceuticals has Return on Asset of (0.0914) % which means that on every $100 spent on assets, it lost $0.0914. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2376) %, meaning that it generated no profit with money invested by stockholders. Universe Pharmaceuticals' management efficiency ratios could be used to measure how well Universe Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.14. The current year's Return On Capital Employed is expected to grow to -0.18. At present, Universe Pharmaceuticals' Intangibles To Total Assets are projected to slightly decrease based on the last few years of reporting.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.7 K | 4.6 K | |
| Tangible Book Value Per Share | 6.7 K | 4.6 K | |
| Enterprise Value Over EBITDA | 3.22 | 4.88 | |
| Price Book Value Ratio | 0.02 | 0.02 | |
| Enterprise Value Multiple | 3.22 | 4.88 | |
| Price Fair Value | 0.02 | 0.02 | |
| Enterprise Value | -18.6 M | -19.5 M |
Effective leadership at Universe Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Technical Drivers
As of the 21st of July, Universe Pharmaceuticals has the Coefficient Of Variation of 2723.04, risk adjusted performance of 0.0432, and Semi Deviation of 6.77. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Universe Pharmaceuticals, as well as the relationship between them.Universe Pharmaceuticals Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Universe Pharmaceuticals for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Universe Pharmaceuticals short-term fluctuations and highlight longer-term trends or cycles.
Universe Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Universe Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Universe Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Universe Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
White John V over a month ago Disposition of 6468 shares by White John V of Universe Pharmaceuticals at 27.75 subject to Rule 16b-3 | ||
White John V over three months ago Acquisition by White John V of 1222 shares of Universe Pharmaceuticals subject to Rule 16b-3 | ||
White John V over a year ago Acquisition by White John V of 10050 shares of Universe Pharmaceuticals at 19.1667 subject to Rule 16b-3 | ||
Trippeer Richard A Jr over a year ago Acquisition by Trippeer Richard A Jr of 6200 shares of Universe Pharmaceuticals at 33.48 subject to Rule 16b-3 | ||
Moore Jackson W over a year ago Acquisition by Moore Jackson W of 308212 shares of Universe Pharmaceuticals at 29.22 subject to Rule 16b-3 | ||
Moore Jackson W over a year ago Acquisition by Moore Jackson W of 13100 shares of Universe Pharmaceuticals subject to Rule 16b-3 |
Universe Pharmaceuticals Outstanding Bonds
Universe Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Universe Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Universe bonds can be classified according to their maturity, which is the date when Universe Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Universe Pharmaceuticals Predictive Daily Indicators
Universe Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Universe Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Universe Pharmaceuticals Forecast Models
Universe Pharmaceuticals' time-series forecasting models are one of many Universe Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Universe Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Universe Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Universe Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Universe shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Universe Pharmaceuticals. By using and applying Universe Stock analysis, traders can create a robust methodology for identifying Universe entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.41) | (0.39) | |
| Operating Profit Margin | (0.40) | (0.38) | |
| Net Loss | (0.44) | (0.41) | |
| Gross Profit Margin | 0.30 | 0.47 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Universe Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
| All Next | Launch Module |
Complementary Tools for Universe Stock analysis
When running Universe Pharmaceuticals' price analysis, check to measure Universe Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Universe Pharmaceuticals is operating at the current time. Most of Universe Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Universe Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Universe Pharmaceuticals' price. Additionally, you may evaluate how the addition of Universe Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |